Mass Vaccination: Solutions in the Skin

Glenn, Gregory M.; Kenney, Richard T.

doi:10.1007/3-540-36583-4_14

Cited by 74 publications

(53 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are over 30 clinical programs today with ID delivery of cancer vaccines (at least one of which with the MicronJet600) and likely many more to come. The ability to enhance the skin's potent immune system with ID immunization, to directly target its Dendritic and Langerhans cells, 118,119 and to potentiate the response against cancer cells, remains one of the great challenges and promises of the 21st century. …”

Section: The Future Of Id Delivery Of Vaccines and Immunotherapeuticsmentioning

confidence: 99%

Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future

Levin

Kochba

Hung

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: The Future Of Id Delivery Of Vaccines and Immunotherapeuticsmentioning

confidence: 99%

Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future

Levin

Kochba

Hung

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Intramuscular (IM) administration is widely used for vaccinations, although intradermal (ID) administration has been shown to be safe, well tolerated, less painful [22][23][24] and to require lower doses 22,25,26 due to the higher number of professional antigen presenting cells found in the skin than in the muscle. 27 Therefore, the ID route may be a relevant strategy for mass immunization, and clade B Tat protein has been administered by this route in 2 phase II clinical trials 17 and unpublished data after having shown superior immunogenicity when administered ID rather than subcutaneously in phase I clinical trials. 18,19 At the same time, the oral administration is gaining interest for its high compliance and the capability of inducing mucosal responses.…”

mentioning

confidence: 99%

Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide

Finessi

Nicoli

Gallerani

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The use of the Tat protein of HIV in vaccines against AIDS showed promising results in primate and human studies. To characterize the impact of the administration route on the induction of humoral responses at systemic and mucosal levels, we compared intradermal, intramuscular and mucosal immunizations with Tat and a Tat-derived peptide. Mice were immunized with the Tat protein by different routes and the titer and isotype of anti-Tat antibodies were assessed in serum and mucosal lavages. Intramuscular and intradermal administrations showed comparable immunogenicity, while the mucosal administration was unable to induce IgM in serum and IgG at mucosal sites but showed superior immunogenicity in terms of IgA induction. Anti-Tat antibodies were also obtained upon vaccination with the immunodominant Tat 1–20 peptide which was, however, less immunogenic than the whole Tat protein

show abstract

“…It has been suggested that the intradermal administration of antigen may activate specific epidermal cells and may be capable of inducing an effective lymphocyte response. 68 Many Langerhans cells, which are very capable antigen-presenting cells, are present in the epidermal area and are thought to participate in enhancing the immune response. A lower dosage also allows largescale vaccination in the community at a lower cost.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B virus infection and related factors in hemodialysis patients in China – systematic review and meta-analysis

et al. 2010

View full text Add to dashboard Cite

Aims: To provide a comprehensive and reliable tabulation of available data on the epidemiological characteristics and risk factors for hepatitis B virus (HBV) infection in maintenance hemodialysis (HD) patients in China and help to inform prevention programs and guide future research. Methods: A systematic review was constructed based on the computerized literature database. Confidence intervals (95% CI) of infection rates were calculated using the approximate normal distribution model. Odds ratios (OR) and 95% CI were calculated by fixed or random effects models. Hepatitis B surface antigen positivity (HBsAg (+)) was set as the sign of HBV infection. Results: Fifty studies met our inclusion criteria. The pooled prevalence of HBV infection among HD patients in China was 11.9%. Blood transfusion was correlated with an increase in HBV infection (p = 0.05). HD patients with a long-term history were more likely to be infected than those with a short-term history. The levels of alanine aminotransferase were higher in the HBsAg (+) patients (p < 0.001). Large doses of HBV vaccine (80 μg/dose) increased the seroconversion rate. The response rate of intradermal injection of HBV vaccine was higher than that of intramuscular injection. Conclusion: Hepatitis B is still one of the main complications in HD patients in China, and the frequency of blood transfusion and duration of HD were the risk factors. Large doses and intradermal injection of HBV vaccine were recommended to prevent HBV infection in HD patients. The findings of this meta-analysis have implications for optimal prevention and treatment of Hepatitis B in HD patients.

show abstract

Mass Vaccination: Solutions in the Skin

Cited by 74 publications

References 49 publications

Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future

Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future

Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide

Hepatitis B virus infection and related factors in hemodialysis patients in China – systematic review and meta-analysis

Contact Info

Product

Resources

About